We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

AI Algorithm Processes MRI and Cognitive Scores to Predict Progression to Alzheimer's Dementia

By MedImaging International staff writers
Posted on 17 Jan 2024
Print article
Image: The AI algorithm predicts the likelihood of progression from aMCI to Alzheimer\'s dementia within five years (Photo courtesy of 123RF)
Image: The AI algorithm predicts the likelihood of progression from aMCI to Alzheimer\'s dementia within five years (Photo courtesy of 123RF)

Globally, over 100 million patients are struggling with amnestic mild cognitive impairment (aMCI), a condition that can either stabilize, improve, or progress to Alzheimer’s dementia. Accurate prognosis assessment is critical for developing effective care and treatment plans. Typically, physicians conduct cognitive function tests and order a brain MRI scan for these patients. Now, a revolutionary medical AI algorithm improves the assessment process by integrating brain MRI data with cognitive test scores to produce a score between 0 and 100. This score aids doctors in determining the likelihood of a patient’s progression from aMCI to Alzheimer’s dementia.

Darmiyan’s (San Francisco, CA, USA) BrainSee is the first FDA-approved medical software designed for evaluating the prognosis of aMCI patients. BrainSee represents a significant advancement in the field, combining state-of-the-art image processing and medical AI to set a new benchmark in predicting the transition from aMCI to Alzheimer's dementia. This innovation offers a fully non-invasive, accessible, and convenient screening tool, prioritizing it before other tests or treatments. BrainSee is a clinical application of Darmiyan's core proprietary technology, which is grounded in over 40 years of advanced brain science. It utilizes a highly scalable, fully-automated platform that merges standard clinical brain MRI and cognitive assessments – routine procedures for patients experiencing memory concerns – to generate an objective score predicting the likelihood of progression to Alzheimer's dementia within five years.

BrainSee's early screening and risk stratification capabilities allow for timely, personalized treatments for high-risk aMCI patients, aiming to delay the onset of dementia. It also offers reassurance to those at lower risk, potentially reducing the need for more invasive and expensive tests. This shift from prolonged anxiety to proactive management is crucial in the era of emerging Alzheimer's treatments, where precise prognoses can guide the selection of suitable treatment candidates. BrainSee is poised to have a significant economic impact on healthcare, potentially reducing the billions spent annually on Alzheimer’s care through more effective management and treatment. Its standout features include prognostic accuracy, patient convenience, immediate test results, and seamless integration into clinical workflows. The widespread availability of MRI further enhances BrainSee's clinical utility, marking a paradigm shift in aMCI workup from biomarker-based methods – often limited by invasiveness, non-specificity, cost, and inaccessibility – to non-invasive and actionable forecasts of future improvement or progression.

"Our vision is to redefine brain health screening and monitoring standards and impact the lives of patients and their family members in a meaningful way," stated Dr. Padideh Kamali-Zare, Founder and CEO of Darmiyan. “BrainSee is the first product of this vision, backed by our solid technological infrastructure that is capable of driving further transformations and scalable innovations in the brain health landscape.”

Gold Member
Solid State Kv/Dose Multi-Sensor
Imaging Table
Stille imagiQ2
Dose Calibration Electrometer
PC Electrometer
Digital Radiography System
DuraDiagnost F30

Print article



view channel
Image: LumiGuide enables doctors to navigate through blood vessels using light instead of X-ray (Photo courtesy of Philips)

3D Human GPS Powered By Light Paves Way for Radiation-Free Minimally-Invasive Surgery

In vascular surgery, doctors frequently employ endovascular surgery techniques using tools such as guidewires and catheters, often accessing through arteries like the femoral artery. This method is known... Read more


view channel
Image: Intravascular ultrasound provides a more accurate and specific picture of the coronary arteries (Photo courtesy of 123RF)

Intravascular Imaging Significantly Improves Outcomes in Cardiovascular Stenting Procedures

Individuals with coronary artery disease, which involves plaque accumulation in the arteries leading to symptoms like chest pain, shortness of breath, and heart attacks, often undergo a non-surgical procedure... Read more

Nuclear Medicine

view channel
Image: The PET imaging technique can noninvasively detect active inflammation before clinical symptoms arise (Photo courtesy of 123RF)

New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear

Rheumatoid arthritis, the most common form of inflammatory arthritis, affects 18 million people globally. It is a complex autoimmune disease marked by chronic inflammation, leading to cartilage and bone... Read more

General/Advanced Imaging

view channel
Image: Routine chest CT holds untapped potential for revealing patients at risk for cardiovascular disease (Photo courtesy of Johns Hopkins)

Routine Chest CT Exams Can Identify Patients at Risk for Cardiovascular Disease

Coronary artery disease (CAD) is the primary cause of death globally. Adults without symptoms but at risk can be screened using EKG-gated coronary artery calcium (CAC) CT scans, which are crucial in assessing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.